CRISIL has upgraded rating for Ipca Laboratories’ long term bank facilities from 'AA-/Positive' to 'AA/Stable' and has also reaffirmed the ratings at 'P1+' for its short term facilities i.e. Rs 1.5 billion Short Term Debt and Rs 2.2 billion Letter of Credit.
The credit rating agency has also upgraded the rating for its Rs 500 million Non-Convertible Debentures, Rs 4.3 billion Cash Credit, Rs 180 million Long-Term Loan and Rs 1,000 million Proposed Long-Term Bank Loan Facility from AA-/Positive to AA/Stable.
Ipca Laboratories is engaged in manufacturing of active pharmaceutical ingredients and formulations. It operates in 110 countries and its export accounts for 50% of the company’s income. Worldwide the company is one of the largest suppliers of APIs and intermediates. The company holds leadership position in Anti-malarial and Rheumatoid Arthritis area.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1803.60 |
| Dr. Reddys Lab | 1282.40 |
| Cipla | 1323.85 |
| Zydus Lifesciences | 904.95 |
| Lupin | 2346.40 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: